Medical/Pharmaceuticals
Senior Vice President at United Imaging Inducted to the AIMBE College of Fellows
HOUSTON, April 1, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technology, is proud to announce thatLingzhi (Lance) Hu, Ph.D., Senior Vice President and Chief Technology Officer of United Imaging Research at United Imaging, has been inducted into the 2025 C...
2025-04-01 21:00
2209
Peijia Medical collaborates with dsm-firmenich to create groundbreaking innovative medical device products
SUZHOU, China, April 1, 2025 /PRNewswire/ -- Today, April 1st, Peijia Medical Technology (Suzhou) Co., Ltd. held a strategic innovation cooperation signing ceremony and a press conference to announce the research and development achievements of polymer heart valves using ultra-high molecular weig...
2025-04-01 20:00
3033
Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting
SHANGHAI, April 1, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that results of its investigational drug candidatesDZD8586 and DZD6008, have been selected for pr...
2025-04-01 18:18
2718
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: KGF alternative peptide (FGFR2b agonist)
TOKYO, April 1, 2025 /PRNewswire/ -- PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte growth factor ...
2025-04-01 14:30
2355
ECHO IQ SIGNS STRATEGIC PARTNERSHIP AND INTEGRATION AGREEMENTS WITH SCIMAGE AND MEDAXIOM TO EXPAND ECHOSOLV AS ACROSS 36 US CARDIOLOGY NETWORKS
* EchoSolv AS will be fully integrated into ScImage's medical workflow platform, facilitating streamlined deployment within MedAxiom's hospital and cardiology networks. * ScImage is a nationally recognised Cloud and integrated workflow management platform, with over 1,200 users, specialisin...
2025-04-01 13:39
2708
Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib
SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee ofUSD85.0 million, under the licensing agr...
2025-04-01 08:48
3541
Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research
Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics...
2025-03-31 21:00
2428
Harbour BioMed Reports Full Year 2024 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its ...
2025-03-31 18:13
3366
Smartee Pioneers a New Phase in Orthodontics with Silicon Valley Founder Mode
SHANGHAI, March 30, 2025 /PRNewswire/ -- As the clear aligner business enters the second quarter of 2025, it shows a promising growth trend. With increasing competition and innovation in the market, Smartee Denti-Technology remains committed to its "Founder Mode," aiming to seize new business opp...
2025-03-31 10:59
2397
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Key Highlights: * Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). * ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS H...
2025-03-31 02:32
3564
Zylox-Tonbridge Announces 2024 Annual Results: Achieves Full-Year Profit for the First Time with Net Profit Exceeding USD 14 Million
HANGZHOU, China, March 28, 2025 /PRNewswire/ -- On March 20, Zylox-Tonbridge Medical Technology Co., Ltd. (Stock Code: 2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") released its 2024 annual results. In 2024, the Company reported revenue ofUSD 109.4 million, a year-on-yea...
2025-03-29 11:53
6627
LifeTech Scientific Corporation Announced 2024 Annual Results: Revenue Exceeded RMB1.3 billion, and International Business Increased by 26%
SHENZHEN, China, March 28, 2025 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiari...
2025-03-29 01:24
5701
Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024
HONG KONG, March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services inHong Kong, today announced its unaudited financial...
2025-03-28 16:50
3667
Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP (Current Good Manufacturing Practices) on-site inspection by the U.S. Food and Drug Administration (...
2025-03-28 15:46
2330
IASO Bio Announces Approval of New Drug Application for Equecabtagene Autoleucel by the Macau Pharmaceutical Administration Bureau
SHANGHAI, NANJING, China and SAN JOSE, Calif., March 28, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that the Pharmaceuti...
2025-03-28 12:55
2300
Fangzhou Inc. Named Among Guangzhou's Top AI Innovators for Intelligent Healthcare Platform
GUANGZHOU, China, March 27, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, has been named to the 2024 Guangzhou Artificial Intelligence Innovation Development List as "Most Promising Enterprise," while its H2H Smart Healthc...
2025-03-28 11:08
2301
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
Financial Performance: Strong Year-over-Year Improvement - Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income. - Net Loss Reduction: 71.5% year-over-year improvement. Key Product Advancements - Sugemalimab (Anti-PD-L1 mAb) - Regulatory...
2025-03-27 19:55
3829
Tigermed Reports Full Year 2024 Results
HANGZHOU, China, March 27, 2025 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...
2025-03-27 18:48
3655
DeepCare Unveils Game-Changing Dental AI Agent at IDS 2025
COLOGNE, Germany, March 27, 2025 /PRNewswire/ -- From March 25 to 29, 2025, DeepCare, a global leader in dental AI, showcases its Multimodal Dental AI Agent and newly upgraded CBCT AI features at the International Dental Show (IDS 2025) inCologne, Germany. As the world's largest and most influent...
2025-03-27 16:00
1915
Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
* STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched onMarch 12, 2025 * Celltrion's adalimumab-aaty was previously added to the Costco Member Prescription Program inAugust 2024 JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc.,...
2025-03-27 13:29
2107
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 320 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 319 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 278 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 257 media titles]
2026-02-17 14:16SMU MBA Rises in FT Global Rankings, Excelling in ESG, Salary and Value-for-Money
[Picked up by 251 media titles]
2026-02-16 08:00